Senores Pharmaceuticals Ltd (SENORES) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Senores Pharmaceuticals reported strong Q1 FY26 results, with consolidated revenue growth of 72% YoY.
- Regulated market revenue increased by 69% YoY and 40% QoQ, driven by existing product portfolio and CDMO/CMO contributions.
- Emerging market revenue grew by 32% YoY, with improved realizations from niche molecules and evolving go-to-market strategies.
- The company achieved positive operating cash flow in Q1 FY26.
- Senores expects 50% top-line growth and 100% PAT growth for FY26.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.